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Abstract 
Aim  
We compared two Botulinum toxin A (BoNT-A) injection frequency regimens, 12-monthly 
versus 4-monthly, for spastic equinus in a randomised clinical trial. The primary outcome 
measure was passive ankle dorsiflexion.  
   
Method   
Forty-two ambulant children with spastic equinus, secondary to cerebral palsy, mean age 3 
years 6 months (SD 13 months) were randomised to receive either 12-monthly or 4-monthly 
BoNT-A injections to the calf, over a 26-month period. Twenty-one children had spastic 
hemiplegia, 21 children had spastic diplegia. A fixed 6U/Kg dose of Botox® was injected 
into the gastrocnemius muscle of both limbs in children with diplegia and the gastrocsoleus 
of the affected limb in children with hemiplegia, under mask anaesthesia.  
 
Results   
Forty-two children entered the trial with 21 subjects randomised to each group. There were 
three withdrawals, and two children received serial casting midway through the trial. There 
was no significant difference in passive dorsiflexion between 12-monthly and 4-monthly 
regimens (p=0.41). There were also no significant between group differences on secondary 
outcome measures. There were no serious adverse events, the rate was 1.2 adverse 
events/child/year in the 12-monthly group and 2.2 adverse events/child/year in the 4-monthly 
group. Subgroup analysis revealed a significant difference in passive dorsiflexion between 
children with hemiplegia and diplegia (p=0.01).  
 
Interpretation   
There was no significant difference between 12-monthly and 4-monthly injection regimens 
on passive dorsiflexion or secondary outcome measures. BoNT-A injections for spastic 
equinus may be recommended on a 12-monthly basis. 
 
What this paper adds 
 Injecting of BoNT-A once each year was as effective as injecting three times per year, 
for young children with cerebral palsy and spastic equinus. 
 Children with spastic hemiplegia had different responses to those with spastic 
diplegia. 
 Injections of BoNT-A for spastic equinus may be recommended on a 12-monthly 
basis. 
 
Level of Evidence   
Level I: Prospective, parallel-group randomised clinical trial.  
 
Key words spastic equinus, cerebral palsy, botulinum toxin A, RCT. 
 
Shortened form of title: 
Injection frequency for spastic equinus. 
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Equinus is the most common gait abnormality affecting children with cerebral palsy 
(CP)1. Calf spasticity increases until the age of four years and then decreases until age 12 
years, during which time many children develop a fixed contracture2. In the Swedish CP-UP 
study, this was associated with a 19° reduction in the mean range of ankle dorsiflexion 
between birth and age 18 years3,4. In children with CP, muscles are shorter with reduced 
volume, cross-sectional area and muscle thickness5. During the early childhood phase of 
spastic equinus, calf lengthening surgery may be unpredictable6 and non-operative methods 
for maintaining muscle length are often preferred. 
Injection of Botulinum toxin-A (BoNT-A) for spastic equinus produces a dose-
dependent partial chemodenervation resulting in reduced muscular activity for approximately 
12-16 weeks7. Reduction in tone and spastic reflexes permits increased passive stretch, which 
has been assumed to increase muscle growth7. In juvenile hereditary spastic mice, injection of 
BoNT-A prevented equinus contracture8. However, this has not been replicated in children 
with CP, most likely attributable to the longer growth period.  In one clinical study of 
children with spastic equinus, injection of the gastrocnemius with BoNT-A resulted in 
gastrocnemius lengthening for 24 weeks9.  
Reasonable evidence and consensus exists regarding the dose of BoNT-A injection to 
the gastrocnemius, for the management of spastic equinus7,10. In one dose-ranging study, 
intermediate doses produced the best response for muscle length during gait11. An optimal 
dose exists, above which the benefits declined, probably related to spread of BoNT-A to 
adjacent muscles and the effects of generalised weakness. 
In ambulant children, GMFCS I-III, injection of BoNT-A in accepted doses is usually 
well tolerated and relatively safe7,12. A Cochrane review of three published randomised 
controlled trials (RCTs) found the evidence for BoNT-A in the management of leg spasticity 
was not strong14. A systematic review of eight RCTs found moderate evidence in support of 
the use of BoNT-A combined with usual care or physiotherapy for children with CP15. In a 
systematic review, BoNT-A was reported to increase ankle dorsiflexion range16.  
Injection of BoNT-A for spastic equinus fails in some children17. Unresponsiveness 
can be primary when it fails the first time, or secondary when it is initially successful but fails 
after subsequent injections7. Although secondary unresponsiveness has been correlated with 
neutralising antibody (NAB) formation, the presence of NAB without treatment failure may 
be more frequent than therapy failure due to NAB7,17. Patient-based testing of motor function 
is an alternative method for detecting the presence of secondary unresponsiveness7. 
In contrast to the consensus and evidence about dose7,10, no consensus and little 
evidence exists about injection frequency for spastic equinus in children with CP. In the only 
injection frequency RCT published to date, Kanovský and colleagues were unable to detect a 
significant difference between 12 monthly and 4 monthly injections over a two-year period13. 
This was a large study with well-accepted outcome measures, including ankle dorsiflexion by 
standard goniometry and the Gross Motor Function Measure13.  
Elsewhere in the literature, recommendations regarding injection intervals range 
between three and 12 months, based largely upon factors such as clinical intuition, avoidance 
of antibody formation, convenience, and cost7,9,10. Prescribing information supplied with 
Botox® (Allergan Pharmaceuticals) does not include evidence-based recommendations for 
frequency of treatment to the lower limbs in children with cerebral palsy. Establishing 
optimal frequency of BoNT-A treatment could be of considerable benefit to patients, service 
providers and health care economists. An essential part of the scientific method is to replicate 
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novel studies. The primary aim of this study was therefore to investigate the optimal 
frequency of BoNT-A injections for the treatment of spastic equinus, using similar injection 
regimens but with different outcome measures13. 
The International Classification of Functioning, Disability and Health (ICF) model 
from the World Health Organization was used to guide selection of outcome measures. The 
primary outcome measure was passive dorsiflexion with the knee extended, a proxy measure 
for the length of the gastrocnemius muscle-tendon unit. Secondary outcome measures were 
motor responsiveness, functional mobility and child health-related quality of life 18. The 
primary hypothesis to be tested was: 
1. Ambulant children with spastic equinus, who receive 4-monthly BoNT-A injections will 
have greater passive ankle dorsiflexion after two years than children receiving 12-
monthly injections. 
Secondary aims were to study: 
2.  a) Differences in motor responsiveness to BoNT-A injections between the two groups at 
the end of the clinical trial. 
b) Differences in function or health-related quality of life between the two groups. 
Method 
Trial Design, Ethical Approval and Study Funding 
Ethical approval was given by each institution’s Human Research and Ethics 
Committee (Royal Children’s Hospital: 27062C, Monash Children’s Hospital: 07083C). 
Written, informed consent was obtained from the parents of all children prior to study 
inclusion. The reporting in this trial follows the CONSORT guidelines.  
This was a two-centre, 26 month, prospective, parallel-group RCT comparing two 
injection frequencies of BoNT-A injections for spastic equinus. The trial was entered on the 
Australia and New Zealand Clinical Trials Registry (No. 12607000326493) and funded by 
the Australian National Health and Medical Research Council (Grant No. 454705). No 
pharmaceutical company sponsorship was received in support of this clinical trial.  
Participants 
Inclusion criteria were spastic equinus defined as the absence of heel contact during 
the stance phase of gait, a diagnosis of spastic CP, toxin naïve, age 2-5 years, GMFCS levels 
I-III and greater than 5° passive dorsiflexion in subtalar neutral with the knee extended19. 
Exclusion criteria were lack of consent, previous surgery, contraindications to BoNT-A or 
use of medications that could potentially interact with BoNT-A. The study took place at two 
tertiary paediatric hospitals between December 2007 and October 2012. Children referred for 
BoNT-A spasticity management at both hospitals were screened for trial eligibility and 
invited to participate by the study coordinator (TH-I). 
Interventions  
The calf muscle was injected with a fixed dose of Botox® (Allergan Pharmaceuticals 
Inc. Irvine, CA) 6U/kg body weight at a fixed dilution of 100U in 4.0ml of normal saline. 
Injections were guided by electrical stimulation under mask anaesthesia, to two sites in the 
medial belly and one site in the lateral belly of the gastrocnemius7. Children with spastic 
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diplegia had injections to the gastrocnemius muscle in both lower limbs at a dose of 6U/kg, a 
total dose of 12U/kg. Children with spastic hemiplegia had injection of the gastrocnemius and 
soleus muscles on the affected side7, at a dose of 6U/kg. The maximum total dose was fixed 
at 18U/kg body weight with the difference between the calf muscle dose and total dose 
available for use at other sites, according to clinical indication. Children in both groups were 
reviewed every four months by the study co-ordinator to standardise care, including use of 
ankle-foot orthoses and access to post-injection physiotherapy. 
Primary Outcome Measure 
Passive ankle dorsiflexion at baseline and 26-months was performed under mask 
anaesthesia by an assessor blinded to group allocation. Measurement was performed 
immediately prior to injection, using a precise and reliable method with standard error of 
measurement 3.9° SD 2.0; 95% CI 3.3, 4.0 which has been fully described previously20.The 
applied torque was standardised to 50% body weight, with a digital photograph taken and 
software used to measure passive dorsiflexion20. 
Secondary Outcome Measures 
1. Motor responsiveness to BoNT-A: a three-dimensional gait analysis (3DGA) was 
performed two weeks before and four weeks after the final BoNT-A injection. 
Maximum ankle dorsiflexion was recorded, between 30 and 35% of the gait cycle.  
2. Functional Mobility: at baseline and 26-months, the Functional Mobility Scale (FMS) 
was completed by an assessor blinded to group allocation, and the Gillette Functional 
Assessment Questionnaire (FAQ) was completed by the child’s parent or usual 
carer21,22.  
3. Health-Related Quality of Life (HRQoL): at baseline and 26-months, the Child Health 
Questionnaire (CHQ) was completed by the child’s parent or usual carer18,23. 
4. The incidence of Adverse Events (AEs) due to BoNT-A injection and other factors such 
as fasting or mask anaesthesia, were recorded. AEs were recorded by the study co-
ordinator at clinical review or by interview, within 10 days of each injection episode or 
at next clinical review. A serious adverse drug reaction was defined as death, a life-
threatening adverse experience, hospitalisation or a persistent or significant 
disability/incapacity. Other AEs were classified as mild if no intervention was required, 
or moderate if medical advice or assessment was sought.  
Subgroup Analyses 
Additional subgroup analyses were performed to determine any difference in passive 
dorsiflexion within and between children with hemiplegia and diplegia over the 26-month 
period.  
Sample Size Calculation 
The study was powered to detect a 5° difference in range with 90% power and 0.05% 
confidence on the assumption of a standard deviation of 5°, which equates to a large effect 
size of 1. On this basis, 21 participants were required in each group. The aim was to recruit 
30 subjects per group to allow for potential withdrawals from the study. 
Randomisation 
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Participants were screened for eligibility and enrolled into the study by the study 
coordinator. Following enrolment, participants were randomised to either 12-monthly or 4-
monthly BoNT-A injection groups using a minimisation approach. This allowed even 
distribution between the two groups for potential confounding factors of CP subtype 
(diplegia, hemiplegia), GMFCS level and whether muscles other than the calf required 
injection over the projected 26-month period. The random allocation sequence was computer-
generated by a statistician at a remote location after receiving an email from the study 
coordinator containing subject number and details for minimisation. The statistician then 
emailed the study coordinator with group allocation, who in turn informed the subject and 
family at the first injection session. 
Blinding 
It was not possible to blind children, parents or injectors to group allocation. 
However, outcome assessors and clinical analysts were blinded to group allocation. 
Statistical Methods 
All outcome data were screened for outliers and normality of distribution, with no 
significant departures found. Linear regression equations were performed for passive 
dorsiflexion, motor responsiveness and HRQoL outcomes. Confidence intervals were 
calculated with robust standard errors to allow for excess correlation in measuring different 
legs from the same patient. Passive dorsiflexion was additionally reported as change from 
baseline to assist in clinical interpretation. These change values were derived from the 
average of the differences between final (26-month) and baseline dorsiflexion measures, with 
a t-test to determine the standard error and confidence intervals. Functional mobility (FMS 
and FAQ) was analysed the using the Wilcoxon rank sum test. Effect size was calculated 
using Cohen’s d 24. All analyses were performed by intention-to-treat, with all statistical tests 
two-sided and the significance level set at p=0.05. Statistical analyses were performed using 
Stata® Release 13 statistical software (StataCorp LP College Station Texas). 
Results 
Study recruitment, randomisation and numbers analysed: Figure 1 CONSORT 
Enrolment was slower than expected and ceased after 42 children entered the trial. 
One child with hemiplegia was withdrawn from the 12-monthly group at the first 4-month 
review due to rapid progression to fixed contracture. In the 4-monthly group, two children 
were withdrawn; one (hemiplegia) by parents due to burden of care associated with unstable 
epilepsy and the other (diplegia) by the treating physician having assessed the trial protocol 
as not meeting the clinical needs of the child. Two children in the 12-monthly group did not 
complete the final gait analysis to determine motor responsiveness. There were no other 
missing data. In the 4-monthly group, two children with hemiplegia developed fixed 
contracture during the trial and were managed mid-trial by serial casting. No other children 
received casting during the trial period. These children were included in the intention-to-treat 
analyses. Nineteen children in the 4-monthly group (90%) and 20 in the 12-monthly group 
(95%) completed the trial protocol.  
Baseline Data: Table I 
The groups were similar on all criteria, including the use of AFOs and access to post 
injection physiotherapy.  
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Primary outcome measure: Ankle Dorsiflexion: Table II  
Both groups maintained passive ankle dorsiflexion and there was no significant 
difference from baseline to 26-months between the 12-monthly and 4-monthly injection 
groups (3.3° greater in 12-monthly group 95% CI -4.7, 11.2 p=0.41). The effect size was 
small: 0.15 (95% CI 0.36, 0.66). The difference in mean passive dorsiflexion change was 2.0° 
(95% CI -5.0, 9.1) between injection frequency groups. 
Secondary outcome measures: Table III and Figure 2   
Both injection frequency groups demonstrated motor responsiveness to the final 
injection of BoNT-A, demonstrated by increased dorsiflexion during stance, with no 
significant between group differences (p=0.19, Table III).  
The FMS 50m and the FAQ additional activities score were slightly better in the 4-
monthly group than in the 12-monthly group but this was not significant. No significant 
differences were found for the FMS 5m or 500m distances (Fig. 2A) or functional level 
within the FAQ (Fig. 2B). There were no significant between group differences for any of the 
13 domains of the CHQ.  
Adverse Events: Table IV 
There were no serious adverse events. The incidence of mild and moderate AEs per 
injection was similar between groups, however children in the 4-monthly group had twice the 
number of AEs. The most common AEs were ‘flu-like’ illnesses, localised muscle pain, and 
falls. Two children attended the Emergency Department on the evening of BoNT-A injection. 
One child had a dose of medication for epilepsy omitted, whilst fasting for injection of 
BoNT-A and presented with seizures. The other child presented with post injection vomiting.  
Subgroup analyses: Table V 
Children with hemiplegia had much less passive dorsiflexion than children with 
diplegia, regardless of injection frequency (p=0.01). The effect size was large for CP subtype: 
0.80 (95% CI 0.24, 1.37). Children with hemiplegia lost an average 8.5° passive dorsiflexion 
whilst those with diplegia gained an average 1.6° over the 26-month study period. There was 
no significant difference from baseline to 26-months when injection frequency was analysed 
for children with hemiplegia (p=0.82) or for children with diplegia (p=0.39).  
Discussion 
Injection of BoNT-A for spastic equinus every four months did not confer any 
advantage over injections every 12 months, for the cohort as a whole, similar to the findings 
by Kanovský and colleagues13. However, both injection groups maintained passive 
dorsiflexion over the two-year study period. This may indicate a benefit over the expected 
natural history but this is impossible to prove without a control group4. We had both ethical 
and practical concerns regarding the inclusion of a “no treatment” control group. We found 
no significant differences in functional mobility, motor responsiveness or child health-related 
quality of life, suggesting a small treatment effect size and that neither group was 
disadvantaged. The rate of adverse events was similar between groups and consistent with 
previous studies11-13. An additional confounder in the study was the variable use of 
concomitant injection of the medial hamstrings, particularly in children with diplegia.  This 
was permitted under study conditions to reflect patient, family and injector preferences.  The 
expected effect would be to improve knee extension by a reduction in “apparent equinus”. 
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New findings, specific to this study relate to the sub-group analyses (Table V). A 
large effect size was seen for the significant difference in passive dorsiflexion between 
children with hemiplegia and children with diplegia, regardless of injection frequency. These 
findings provide important new information to guide injection protocols in children with 
hemiplegia compared to those with diplegia. 
For all children with hemiplegia, there was a mean 8.5° loss of passive dorsiflexion 
over the course of study. There are anecdotal reports that children with hemiplegia progress 
to fixed contracture more quickly than those with diplegia7. The response by many clinicians 
when faced by no response to injection, is to increase the frequency of BoNT-A injections. 
However, this may be the wrong strategy based on our results. In children with hemiplegia, 
the loss of passive dorsiflexion was 9.0° over the 26-month period for those receiving 4-
monthly injections, compared to 8.1° for those undergoing injections every 12-months (Table 
V). Tripling the frequency of injection does not prevent progressive contracture in children 
with hemiplegia. Our recommendations are to assess the response on an individual basis and 
cease injections of BoNT-A when fixed contracture develops, with early referral for surgical 
lengthening of the fixed contracture. 
Unlike children with hemiplegia, there were important differences for injection 
frequency in children with diplegia. For children with diplegia as a whole, mean passive 
dorsiflexion increased from 7.7° to 9.9° at 26-months (Table V). Children with diplegia 
receiving 12-monthly injections maintained their range of passive dorsiflexion, which 
increased slightly from 6.6° to 7.5°. However, those undergoing 4-monthly injections had 
increased passive dorsiflexion from 8.7° to 12.4°. For some children with diplegia and 
muscle weakness, the increase in ankle dorsiflexion was excessive when individual gait 
studies were reviewed. In these children, increased ankle dorsiflexion was achieved at the 
cost of increased knee flexion, a most undesirable outcome1,6. 
In children with hemiplegia, lower limb involvement is more pronounced distally than 
proximally and crouch gait is unknown6. In children with diplegia, the knee, not the ankle is 
the problem level and crouch gait, as part of natural history or the result of intervention, is 
very common1,6. Mild equinus may help direct the ground reaction force in front of the knee, 
providing protective coupling and knee extension. We conclude that the frequency of 
injection in children with diplegia should be once every 12 months. More frequent injections 
may result in longer, weaker, incompetent gastrocsoleus muscles, predisposing the child to 
the development of crouch gait. In children with diplegia, “a little equinus is better than 
calcaneus”6. 
In conclusion, our study-based treatment recommendations are for 12-monthly 
injections for the management of spastic equinus in children with hemiplegia and children 
with diplegia. Children with hemiplegia do not benefit from increased frequency of 
injections. The progression to fixed contracture occurs early in childhood and is not amenable 
to increased injection frequency. Emerging evidence from animal studies suggests that 
repeated BoNT-A injection before full muscle recovery may lead to dramatically increased 
reductions in muscle torque, and pathological changes within skeletal muscle including 
fibrosis and fatty infiltration25. For children with diplegia, increased injection frequency may 
achieve “foot flat” which is often regarded by parents and clinicians as a good outcome.  
However foot flat and dorsiflexion even within the “normal range” may increase the risk of 
crouch gait. In ambulant children with CP, a 12-monthly injection regimen will offer the 
same degree of efficacy, fewer adverse events, and greater protection against crouch gait 
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compared with more frequent injections. This will result in substantial savings at a time of 
spiraling healthcare costs. 
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Table I: Baseline demographic and clinical characteristics of the study cohort. 
Baseline Characteristics* 12-monthly group 
n=21 
4-monthly group 
n=21 
Age years, months (SD)  3y 5m (SD 1y 1m) 3y 5m (SD 1y 2m) 
Gender Male 13 10 
 Female 8 11 
CP Classification Hemiplegia 11 10 
 Diplegia 10 11 
GMFCS Level I 11 9 
 Level II 8 11 
 Level III 2 1 
Randomised to receive calf  
+ other muscle injections 
 
13 16 
Usual care: orthotics Solid AFO 14 16 
 Hinged AFO 15 12 
 In-shoe orthotic 2 0 
Usual care: physiotherapy  Matched funding: equal post injection 
therapy available to both groups 
* There were no significant differences in baseline characteristics between the two groups 
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Table II: Ankle dorsiflexion for injection frequency groups 
Passive 
Dorsiflexion  
Baseline 26 months Change  
 Mean  SD Mean  SD Mean  SD  Mean difference between 
groups at 26mths 
95% CI p 
12-monthly 7.4° 12.8° 5.3° 14.3° -2.7° 14.1° 
3.3° -4.7°, 11.2° 0.41 
4-monthly 8.3° 9.4° 8.6° 9.3° -0.7° 12.7° 
Difference: mean 95% CI    2.0° -5.0°, 9.1°    
Negative (-) values for change scores indicate a loss of mean dorsiflexion range; positive (+) values indicate a gain in mean dorsiflexion range. The change 
scores may not reflect the apparent difference between baseline and 26 months due to some missing data at follow-up.
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Table III: Motor responsiveness to Botulinum toxin-A: Maximum ankle dorsiflexion from 3DGA  
Motor responsiveness  
to BoNT-A 
12-monthly  
injection group 
mean (SD) 
4-monthly  
injection group 
mean (SD) 
Mean 
difference 
between 
groups* 
95% CI 
 
p 
 
 Pre-injection Post-injection Pre-injection Post-injection 
Maximum ankle dorsiflexion (°) -4.6° (17.9) +3.2° (17.0) +3.9° (13.4) +10.0° (10.8) 6.8° -3.4, 17.0 0.19 
Negative (-) values indicate equinus; positive (+) values indicate dorsiflexion.  
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Table IV: Adverse Events 
* 21 children per group. 
 
Adverse events 
 
12-monthly  
Total injection episodes = 61 
4-monthly  
  Total injection episodes = 140 
 
Injection episodes associated with 1 or 
more mild-moderate AEs 
26 47  
Injection episodes with no AEs 35 93  
Mild-moderate AE rate per injection 
episode 
43% 34%  
AE per child per year of treatment* 1.2 2.2  
Total mean dose per injection, Units (SD) 183U (78U) 185U (79U)  
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Table V: Subgroup analyses: Ankle dorsiflexion  
Negative (-) values for change scores indicate a loss of mean dorsiflexion range; positive (+) values indicate a gain in mean dorsiflexion range.  
  
 
 
 
Subgroup Analyses  
Passive Dorsiflexion  
Baseline 26 months Change  
Mean SD Mean SD Mean 
 
SD Mean 
difference 
between groups 
at 26mths 
95% CI p 
Both injection 
frequencies 
Hemiplegia 8.1° 15.0° 0.5° 9.4° -8.5° 14.0° 
9.4° 2.6°, 16.2° 0.01 Diplegia 7.7° 8.7° 9.9° 12.2° +1.6° 12.0° 
Difference: mean, 95% CI    10.1° 3.1°, 17.2° 
Hemiplegia 12-monthly 8.8° 17.5° 1.0° 11.5° -8.1° 16.3° 
-1.0° -10.1°, 8.1° 0.82  4-monthly 7.3° 12.5° 0.0° 7.0° -9.0° 11.9° 
 Difference: mean, 95% CI    -0.9° -14.8°, 13.0° 
Diplegia 12-monthly 6.6° 9.7° 7.5° 15.3° +0.1° 12.2° 
5.0° -5.9°, 15.8° 0.39  4-monthly 8.7° 8.0° 12.4° 7.4° +3.1° 11.5° 
 Difference: mean, 95% CI    2.9° --4.8°, 10.6° 
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Figure 1: CONSORT diagram of the study  
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Figure 2: Mobility scales. A. Functional Mobility Scale, B. Functional Activity Questionnaire: Level, C. Functional Activity Questionnaire: 
Activities. Median change and interquartile range (IQR) scores for the 12-monthly (12m) and 4-monthly (4m) injection frequency groups are 
shown. Box depicts upper and lower quartiles with median subdividing the box, unless it falls on the quartile range. Whiskers span all data 
points within 1.5 IQR of the upper and lower quartiles. Dots represent outlying data points. 
 
